Medical Marijuana, Inc. the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Company’s major investment company AXIM® Biotechnologies, Inc. (“AXIM”), a world leader in cannabinoid research and product development, has signed a cannabinoid product supply agreement with Impression Healthcare Limited (“Impression”). The agreement states that AXIM will supply its patented toothpaste and mouthwash containing cannabidiol (CBD) for Impression’s clinical trial for the treatment of periodontitis.
“Medical Marijuana, Inc. is proud to be a cannabis industry leader. As part of that leadership, we aim to set an example by aiding in the research deeply needed throughout the industry,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “AXIM’s agreement with Impression Healthcare to provide the necessary materials for a clinical trial on CBD for the indication of periodontitis continues our dedication to research.”
The supply agreement is in preparation for a clinical trial testing the effectiveness of CBD in treating periodontitis, to be performed at Swinburne University of Technology in Melbourne, Australia.
In accordance with the agreement, AXIM will supply the first batch of its patented toothpaste and mouthwash products containing CBD, along with associated placebo units for Impression to perform a randomized control clinical trial.
“Periodontitis affects people in every part of the globe and we aim to provide a natural and easily accessible treatment for those suffering from the disease,” said AXIM CEO John W. Huemoeller II. “AXIM has seen great success in using oral delivery systems for treatment with its patented cannabinoid-based chewing gum and looks forward to expanding its ability to treat a variety of indications through our recent patent for toothpaste and mouthwash containing CBD and CBG.”
Oral diseases are the most common noncommunicable diseases across the globe according to the World Health Organization. The World Health Organization also estimates severe periodontal disease to be the 11th most common disease worldwide.
Impression Healthcare Limited is an innovative healthcare company that sells customized oral devices both direct-to-consumer and via the company’s growing B2B preferred practitioner network of dentists. With its own laboratory in Victoria, Australia, Impression offers best-in-class teeth protection and helps its customers to combat bruxism, snoring, mild-to-moderate sleep apnea and teeth discoloration with custom-fitted oral devices.